Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512.
about
Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanomaUveal melanoma: From diagnosis to treatment and the science in between.Management of uveal melanoma: a consensus-based provincial clinical practice guidelineBiology of advanced uveal melanoma and next steps for clinical therapeutics.Double-blinded, randomized phase II study using embolization with or without granulocyte-macrophage colony-stimulating factor in uveal melanoma with hepatic metastasesResults of a Phase II Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Patients Who Failed First-Line Therapy Containing Dacarbazine.Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic ReviewSorafenib in metastatic uveal melanoma: efficacy, toxicity and health-related quality of life in a multicentre phase II study.Systemic treatment of metastatic uveal melanoma: review of literature and future perspectivesClinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience.Evolving systemic targeted therapy strategies in uveal melanoma and implications for ophthalmic management: a review.Update on Metastatic Uveal Melanoma: Progress and Challenges.Emerging growth factor receptor antagonists for the treatment of advanced melanoma.Histologic and immunohistochemical predictors of clinical behavior for feline diffuse iris melanoma.Recent advances in uveal melanoma treatment.Treatment of uveal melanoma: where are we now?
P2860
Q28543960-DD2837EA-1542-462C-9572-A00F66434184Q30251762-DED61150-C9AC-4400-B4A7-0556E2D3A013Q30388575-DD450A35-983D-4C22-8F71-9BC6FFD3D501Q35079709-FD5FD3D8-F8D3-4A01-AA1B-9A3938C93C4FQ35563368-BBC13830-58AD-45EE-B2E0-A74B7A95B6B0Q36187013-C92B3659-905F-49D2-98C7-DCA3906D4CECQ36270115-0A005F06-4F14-4566-905E-C285D500A7B7Q37061324-42080480-CDAB-45AB-8139-9BD2B5A6B1C1Q37482566-CDCB712F-7B02-4AAA-BD01-89F16BC3C64CQ37701881-8C970008-22EA-4657-B46B-65F51751647AQ38646057-163DE4FD-41E2-4E0C-AB7B-00658ACB3CD5Q38783505-F0EE625F-5186-4446-9210-42E37A0251B6Q39340696-B219F54E-C4C3-4795-BC50-427EB3CA6A22Q45930485-671BAC4E-F569-45AA-922C-9511A14508FFQ47571643-12AFF326-03A2-4E65-8DBC-83986BD6130AQ50349181-AC7D6EB5-F025-4216-982A-E45772C6741D
P2860
Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512.
description
2012 nî lūn-bûn
@nan
2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Phase II trial of sorafenib in ...... ic uveal melanoma: SWOG S0512.
@ast
Phase II trial of sorafenib in ...... ic uveal melanoma: SWOG S0512.
@en
Phase II trial of sorafenib in ...... ic uveal melanoma: SWOG S0512.
@nl
type
label
Phase II trial of sorafenib in ...... ic uveal melanoma: SWOG S0512.
@ast
Phase II trial of sorafenib in ...... ic uveal melanoma: SWOG S0512.
@en
Phase II trial of sorafenib in ...... ic uveal melanoma: SWOG S0512.
@nl
prefLabel
Phase II trial of sorafenib in ...... ic uveal melanoma: SWOG S0512.
@ast
Phase II trial of sorafenib in ...... ic uveal melanoma: SWOG S0512.
@en
Phase II trial of sorafenib in ...... ic uveal melanoma: SWOG S0512.
@nl
P2093
P2860
P1433
P1476
Phase II trial of sorafenib in ...... ic uveal melanoma: SWOG S0512.
@en
P2093
Ana M Aparicio
Antoni Ribas
Christopher D Lao
James Moon
Jeffrey S Weber
Kim A Margolin
Shailender Bhatia
Vernon K Sondak
P2860
P304
P356
10.1371/JOURNAL.PONE.0048787
P407
P50
P577
2012-11-30T00:00:00Z